Streptokinase

Streptococcal fibrinolysin . An enzyme produced by hemolytic streptococci. It hydrolyzes amide linkages and serves as an activator of plasminogen. It is used in thrombolytic therapy and is used also in mixtures with streptodornase (STREPTODORNASE AND STREPTOKINASE). EC 3.4.-.

Also Known As:

Networked: 3036 relevant articles (212 outcomes, 511 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	White, Harvey D: 15 articles (09/2012 - 06/2002)
2.	Califf, Robert M: 10 articles (09/2013 - 07/2002)
3.	Califf, R M: 9 articles (04/2001 - 03/2000)
4.	Armstrong, Paul W: 8 articles (09/2013 - 07/2002)
5.	French, John K: 7 articles (09/2012 - 01/2003)
6.	White, H D: 7 articles (09/2002 - 03/2000)
7.	Topol, E J: 7 articles (04/2001 - 03/2000)
8.	Manjunath, C N: 6 articles (09/2015 - 05/2005)
9.	Harrington, Robert A: 6 articles (09/2013 - 07/2002)
10.	Gao, Wanzhen: 6 articles (09/2012 - 01/2003)

Related Diseases

1.	Myocardial Infarction 08/01/1981 - "The use of streptokinase (avelisine) in patients with acute myocardial infarction was accompanied by defibrinisation of the blood, by marked decrease of the aggregation facility of formed elements of the blood and its viscosity. " 04/01/2012 - "Following a series of investigations, streptokinase was discovered and demonstrated to be beneficial for the treatment of patients with acute myocardial infarction in terms of reducing short- and long-term mortality. " 01/01/2000 - "Efficacy of rapid infusion of streptokinase in patients with acute myocardial infarction." 03/01/1996 - "Thrombolytic treatment of the acute myocardial infarction with intravenous streptokinase is safe and effective, and may successfully be carried out also in district hospitals in which cardiac catheterization and cardiosurgery are inaccessible." 07/25/1994 - "patients treated with intravenous streptokinase for acute myocardial infarction reach both higher heart rates and rate-pressure products at maximum workload than their controls thus indicating that the beneficial effects of thrombolysis after acute myocardial infarction are reflected in an improved heart rate response during exercise."
2.	Thrombosis (Thrombus) 01/01/2012 - "We describe a primigravida with mitral valve replacement status presenting with acute prosthetic valve thrombosis and treated successfully with intravenous streptokinase." 06/01/2006 - "Acute portal vein thrombosis with associated mesenteric and splenic vein thrombosis is a potentially lethal coagulation disorder that can be treated successfully with systemic streptokinase." 09/01/2005 - "The case is presented of a patient in whom prosthetic heart valve thrombosis was treated successfully with streptokinase under transesophageal echocardiographic guidance." 12/01/1994 - "Streptokinase infused directly into thrombus in arteries even in low doses significantly enhances thrombolysis of vessels which are too small to be cleared by mechanical means. " 08/01/1991 - "A 27 year old patient with a thrombosis of the subclavian vein (Paget- von Schroetter's-syndrome) was treated successfully with a systemic streptokinase thrombolysis. "
3.	Pulmonary Embolism 07/01/2010 - "[Massive pulmonary thromboembolism treated successfully with streptokinase. " 08/01/1976 - "As a result of the case described the administration of streptokinase in a high initial dosage of about 750,000-1,000,000 U within a few minutes appears to be effective in serious lethal pulmonary embolism. " 01/01/1983 - "The efficacy of streptokinase was studied in an open trial on 30 consecutive patients with major pulmonary embolism, affecting at least three lobar arteries in pulmonary angiography. " 01/01/1983 - "It is concluded that streptokinase treatment of major pulmonary embolism is effective and safe in rapidly restoring pulmonary perfusion." 12/01/2001 - "High dose and short-term streptokinase infusion in patients with pulmonary embolism: prospective with seven-year follow-up trial."
4.	Stroke (Strokes) 09/25/1996 - "In contrast, among the 70 patients who were entered into the trial within 3 hours of stroke onset, there was a trend toward improved outcomes for those who received streptokinase (RR of unfavorable outcome, 0.66; 95% CI, 0.28-1.58), and this outcome pattern was significantly better than for those receiving therapy after 3 hours (P=.04). " 07/01/1999 - "We performed a post hoc analysis of MAST-E data designed to assess the safety and efficacy of streptokinase administered intravenously within 6 hours of stroke onset. " 09/06/1993 - "To assess the safety and efficacy of the intra-arterial administration of streptokinase within 24 hours of acute ischaemic stroke. " 10/01/2013 - "Given the lack of therapeutic alternatives in developing countries, a new trial of streptokinase in acute stroke, utilizing stricter inclusion criteria similar to those in more recent thrombolytic studies, appears warranted. " 07/01/2000 - "Individual patient data from the Australian Streptokinase Trial (ASK), Multicentre Acute Stroke Trial-Europe (MAST-E), Multicentre Acute Stroke Trial-Italy (MAST-I), and Glasgow Trial (Glasgow) were pooled. "
5.	Infarction 06/01/1986 - "Comparison of radionuclide left ventricular ejection fraction assessed acutely (28 +/- 10 hours after infarction) with left ventricular ejection fraction at hospital discharge (15 +/- 3 days after infarction) showed no significant improvement in either the streptokinase or control group, 0% and +1%, respectively. " 02/01/1992 - "The streptokinase-induced reduction in blood viscosity may lead to an improvement in microcirculation in the infarction area during the early phase, whereas the hyperviscosity observed independently of therapy after 1 week may lead to an impairment of microcirculation." 10/01/2013 - "Specific features of prior trial designs that may have adversely affected outcomes include a prolonged treatment window, inclusion of patients with established infarction on computed tomography scan, failure to treat excessive arterial pressures, a fixed dose of streptokinase, and concomitant use of antithrombotic medications. " 03/01/2000 - "Two hundred fifty-eight AMI patients from the Thrombolytics and Myocardia Infarction phase 7 and Global Utilization of Streptokinase tPA for Occluded coronary arteries phase 1 trials were stratified based on blinded, simultaneous reperfusion assessment on the acute angiogram (divided into TIMI grades 0 & 1, TIMI grade 2 and TIMI grade 3) and ST-segment resolution analysis (divided into: <50% ST-segment elevation resolution or reelevation and > or =50% ST-segment elevation resolution). " 09/01/1996 - "We studied 24 patients in the Australian Streptokinase Trial with acute middle cerebral cortical infarction using 99mTc-hexamethylpropyleneamine oxime single-photon emission CT. "

Related Drugs and Biologics

1.	Tissue Plasminogen Activator (Alteplase)
2.	Anistreplase (APSAC)
3.	Urokinase-Type Plasminogen Activator (Urokinase)
4.	Heparin (Liquaemin)
5.	Deoxyribonuclease I (Nickase)
6.	Fibrinolytic Agents (Antithrombotic Agents)
7.	Enoxaparin (Lovenox)
8.	Streptodornase and Streptokinase
9.	Immunoglobulin G (IgG)
10.	reteplase

Related Therapies and Procedures

1.	Thrombolytic Therapy
2.	Angioplasty (Angioplasty, Transluminal)
3.	Intravenous Infusions
4.	Catheters
5.	Coronary Balloon Angioplasty (Percutaneous Transluminal Coronary Angioplasty)